Tuberculosis (TB) nursing: assessment, interventions, and NCLEX review

Tuberculosis is one of the most clinically demanding infectious diseases nurses encounter — not because it is complicated to care for in the moment, but because it requires sustained vigilance across weeks to months of treatment, careful infection control, and intensive patient education. TB is caused by Mycobacterium tuberculosis and kills more people globally each year than any other single infectious agent except HIV. In 2022, an estimated 10.6 million people developed active TB worldwide, with 1.3 million deaths (WHO Global TB Report 2023). In the United States, approximately 8,300 active TB cases are reported annually, with disproportionate burden in foreign-born individuals, people experiencing homelessness, those who are incarcerated, and immunocompromised patients.

For nursing students, TB is high-yield on NCLEX and clinically critical for multiple reasons: airborne precaution management, directly observed therapy (DOT), the RIPE drug regimen with hepatotoxicity monitoring, and the distinction between latent and active disease all appear routinely. This reference covers everything from pathophysiology through a complete drug table, isolation protocols, patient education, and six NCLEX-style practice questions. Use alongside the pneumonia nursing reference for respiratory assessment priorities, the sepsis nursing reference for systemic infection progression, and the nursing lab values cheat sheet for LFT and CBC interpretation during TB treatment.

TB at a glance

Pathophysiology

Mycobacterium tuberculosis: why it is difficult to treat

Mycobacterium tuberculosis is an obligate aerobe and a facultative intracellular pathogen. Its defining structural feature is a thick, waxy cell wall composed of mycolic acid — a complex lipid that makes the organism resistant to most disinfectants, highly resistant to drying and environmental exposure, and impermeable to most antibiotics. This cell wall also makes M. tuberculosis acid-fast: when stained with carbol fuchsin and decolorized with acid-alcohol, the organism retains the red stain (a positive AFB smear) because the mycolic acids resist decolorization.

The organism multiplies slowly — doubling time of 12–24 hours compared with 20 minutes for E. coli — which is the primary reason TB treatment requires months rather than days. Antibiotics work by disrupting processes that occur during bacterial replication, so slow-growing organisms require prolonged exposure to achieve sterilizing cure.

Primary TB infection and the Ghon complex

When a susceptible individual inhales droplet nuclei containing M. tuberculosis, the organisms deposit in the terminal alveoli (typically the middle and lower lung zones, where ventilation is greatest). Alveolar macrophages engulf the bacilli but cannot destroy them because M. tuberculosis actively inhibits phagosome-lysosome fusion. The organism survives and replicates within macrophages.

Over 2–10 weeks, cell-mediated immunity develops. CD4+ T lymphocytes recognize mycobacterial antigens and activate macrophages via IFN-gamma secretion. Activated macrophages surround the infection, forming a granuloma — a compact cluster of macrophages, epithelioid cells, Langhans giant cells, and lymphocytes. The center of the granuloma undergoes caseous necrosis (cheese-like necrosis), creating what is called the Ghon focus. When the draining hilar lymph nodes also become involved, the combination is called the Ghon complex (also called the primary complex).

In approximately 90–95% of immunocompetent individuals, the immune response successfully contains the infection at this stage. The granuloma calcifies over time and is visible on chest X-ray as a calcified nodule. The person has latent TB infection (LTBI): a positive tuberculin skin test (TST) or interferon-gamma release assay (IGRA), no symptoms, no active disease, and no infectiousness.

Latent TB infection vs active disease

Latent TB infection (LTBI) represents the quiescent state where viable M. tuberculosis persists inside granulomas but is contained by immune surveillance. An estimated 1.7 billion people — nearly a quarter of the world’s population — have LTBI. Most will never develop active disease. However, lifetime risk of progression to active TB is approximately 5–10% in immunocompetent individuals, with roughly half of that risk occurring in the first two years after initial infection.

Active TB results when immune containment fails and the organism begins replicating beyond granuloma boundaries. This occurs either via primary progressive TB (failure to contain primary infection, more common in infants and immunocompromised patients) or reactivation TB (breakdown of a previously contained latent focus, the most common form in adults). The triggers for reactivation include HIV infection (the single greatest risk factor — annual reactivation risk is 10% vs 0.1% in HIV-negative individuals), malnutrition, diabetes mellitus, end-stage renal disease, anti-TNF therapy (adalimumab, infliximab), prolonged corticosteroid use, and silicosis.

Why pulmonary TB is predominantly upper-lobe

Reactivation TB preferentially involves the apical and posterior segments of the upper lobes and the superior segments of the lower lobes — areas with higher oxygen tension (pO2). Because M. tuberculosis is an obligate aerobe, it thrives in highly oxygenated lung tissue. This upper-lobe distribution is a classic radiographic clue that distinguishes reactivation TB from CAP and other infections.

Clinical presentation

Pulmonary TB: signs and symptoms

Active pulmonary TB is characteristically a subacute to chronic illness. Symptoms develop gradually over weeks to months, which distinguishes TB from most bacterial pneumonias that present acutely. The hallmark symptom pattern on NCLEX and in clinical practice is:

• Productive cough lasting ≥3 weeks (frequently blood-streaked or frankly hemoptysic)
• Night sweats — drenching sweats that soak bedclothes, classically occurring in the early morning hours
• Fever — low-grade, often 37.5–38.5°C, present daily but not typically high-spiking
• Unintentional weight loss — often significant (5–10 kg) by the time of diagnosis
• Fatigue and malaise — profound, progressive
• Anorexia
• Hemoptysis — blood-streaked sputum or frank blood, caused by erosion of pulmonary vessels by cavitary disease

Extrapulmonary TB

TB can affect virtually any organ system. Extrapulmonary TB accounts for approximately 20% of all TB cases in the United States and is more common in immunocompromised patients, children, and foreign-born individuals. Key sites include:

• Lymph nodes (lymphadenitis): Most common extrapulmonary site — painless, firm cervical or hilar lymphadenopathy; nodes may coalesce and drain
• Pleura (pleuritis): Exudative pleural effusion; chest pain, dyspnea; may be the only manifestation of primary infection
• Bone and joint (osteoarticular TB): Spine involvement (Pott’s disease) is most common — vertebral destruction, kyphosis, potential spinal cord compression; long bone and joint involvement also occurs. See the wound assessment guide for draining sinuses associated with bone TB.
• Miliary TB: Hematogenous dissemination creating 1–2 mm granulomas throughout multiple organs; diffuse millet-seed infiltrates on CXR; high mortality if untreated; associated with severe immunocompromise
• CNS (tuberculous meningitis): Most severe extrapulmonary form — subacute onset of meningismus, altered consciousness, cranial nerve palsies; CSF shows lymphocytic pleocytosis with low glucose and high protein
• Genitourinary TB: “Sterile pyuria” (WBCs in urine with negative routine culture) is a classic NCLEX finding; TB must be excluded by mycobacterial urine culture
• Pericardial TB: Pericarditis with effusion; risk of constrictive pericarditis

Diagnosis

Tuberculin skin test (TST / Mantoux)

The TST (Mantoux test) is performed by intradermally injecting 0.1 mL of purified protein derivative (PPD) on the volar forearm. The result is read at 48–72 hours by measuring the induration (not erythema) in millimeters. Interpretation depends on the patient’s risk category:

• ≥5 mm: HIV-positive individuals; close contacts of active TB cases; patients with fibrotic changes on CXR consistent with prior TB; immunosuppressed patients (transplant recipients, anti-TNF therapy, ≥15 mg/day prednisone for ≥1 month)
• ≥10 mm: Foreign-born individuals from high-prevalence countries; injection drug users; residents/employees of high-risk congregate settings (prisons, shelters, nursing homes); healthcare workers; patients with diabetes, CKD, or silicosis
• ≥15 mm: Persons with no identified risk factors for TB

A two-step TST is used for initial screening of healthcare workers — a second test is placed 1–3 weeks after the first negative result to detect boosting (an anamnestic immune response that may convert a negative to positive, preventing misclassification as a new conversion in future annual testing).

Interferon-gamma release assay (IGRA)

The IGRA (QuantiFERON-TB Gold Plus or T-SPOT.TB) is a blood test that measures interferon-gamma released by T cells in response to M. tuberculosis-specific antigens (ESAT-6 and CFP-10). IGRAs have several advantages over TST: a single blood draw, no reader subjectivity, no boosting effect, and no cross-reaction with BCG vaccination (unlike TST). IGRAs are preferred for patients who received BCG vaccine and for those unlikely to return for TST reading. Neither TST nor IGRA distinguishes latent from active TB.

Chest X-ray findings

CXR is essential in the TB workup but not diagnostic alone. Classic findings include:

• Reactivation TB: Upper-lobe infiltrates with or without cavitation; apical and posterior segment involvement; fibrotic or calcified nodules from prior infection (Ghon complex)
• Primary TB: Middle or lower lobe infiltrate (perihilar); hilar lymphadenopathy; pleural effusion
• Miliary TB: Diffuse bilateral 1–2 mm nodules throughout both lung fields

Sputum AFB smear and culture

The sputum AFB smear (acid-fast bacillus smear using Ziehl-Neelsen or auramine-rhodamine staining) is the fastest diagnostic test. Three sputum specimens collected on consecutive days (at least one early morning) are required. A positive smear indicates a high organism burden but does not distinguish M. tuberculosis from other mycobacteria. Sensitivity for pulmonary TB is 45–80%.

Sputum mycobacterial culture is the gold standard — more sensitive (80–90%) than smear and essential for species identification and drug susceptibility testing. Liquid culture systems (MGIT) return results in 1–3 weeks; solid media (Löwenstein-Jensen agar) takes 3–8 weeks. Drug susceptibility testing (DST) on positive cultures identifies resistance to first-line and second-line drugs and guides therapy adjustments.

NAAT (Nucleic Acid Amplification Testing) such as the Xpert MTB/RIF assay can detect M. tuberculosis DNA and rifampin resistance within 2 hours from sputum. CDC recommends NAAT on at least one respiratory specimen for all patients with suspected pulmonary TB.

Nursing assessment

Admission priorities

When a patient with suspected or confirmed active TB is admitted, nursing priorities are:

1. Implement airborne precautions immediately — do not wait for diagnostic confirmation if clinical suspicion is high. Place the patient in a negative pressure room and don N95 before entering.
2. Obtain a focused respiratory history: Duration and character of cough, presence of hemoptysis, sputum production, dyspnea, and prior TB history or TB treatment.
3. Collect three sputum specimens — educate the patient on proper deep-cough technique; early morning specimens have the highest yield. Collect on three consecutive days or within a 24-hour period using an 8-hour interval protocol.
4. Establish baseline vital signs including weight — weight loss is a key clinical indicator.

Respiratory assessment

Perform a complete respiratory assessment every shift:

• Auscultate all lung fields — note crackles, decreased breath sounds (consolidation or effusion), or amphoric sounds over cavitary lesions
• Assess cough frequency, sputum color and volume, and presence of blood-tinged sputum or frank hemoptysis
• Measure oxygen saturation — hypoxemia with extensive disease may require supplemental oxygen
• Monitor respiratory rate and work of breathing

Contact history and social risk factors

Effective TB nursing assessment extends beyond the patient to epidemiological context:

TB screening protocols

Healthcare workers require baseline TB screening at hire (IGRA preferred) and annual testing in high-exposure settings. A TST conversion (≥10 mm increase from prior negative baseline within a 2-year period) or new positive IGRA constitutes a new infection requiring further evaluation and LTBI treatment. All new TB-positive employees must be removed from patient care pending medical clearance.

Nursing interventions

Airborne precautions: the non-negotiable foundation

TB is transmitted by airborne droplet nuclei that remain suspended in room air for hours. Surgical masks do not provide adequate filtration — the nurse must wear a NIOSH-approved N95 respirator (or higher) whenever entering the patient’s room. N95 respirators must be fit-tested to the individual wearer.

Directly observed therapy (DOT)

DOT is the standard of care for all patients with active TB. A trained healthcare provider — nurse, community health worker, or public health TB program staff — watches the patient swallow every single dose of TB medication. DOT is not optional; it is the CDC-recommended standard because:

• TB treatment requires 6 months minimum — adherence rates with self-administered therapy are unacceptably low
• Non-adherence leads to incomplete eradication of organisms, selection for resistant mutants, and drug-resistant TB development
• MDR-TB (multidrug-resistant, resistant to INH and RIF) and XDR-TB (extensively drug-resistant) are clinical and public health catastrophes that are preventable with DOT

Nursing responsibilities for DOT:

• Administer each dose directly and observe the patient swallow
• Document each observed dose in the medication record
• Coordinate with the local health department TB program for post-discharge DOT planning
• Assess barriers to DOT compliance (transportation, work schedule, stigma) and problem-solve with social work
• If a patient refuses DOT or has multiple missed doses, notify the public health TB nurse immediately — most jurisdictions have legal authority to detain non-adherent TB patients who are a public health threat

Infection control priorities

• Minimize the patient’s time outside the AIIR; obtain sputum, labs, and vitals at bedside whenever possible
• When the patient must cough (for sputum collection or during exam), stand to the side rather than directly in front
• Provide the patient with tissues for cough etiquette and a plastic bag for tissue disposal inside the room
• Use dedicated patient equipment (stethoscope, BP cuff) — label and keep inside the room
• Report active TB cases to the local health department within 24 hours in most jurisdictions (reporting requirements vary by state)

Monitoring for drug side effects

During RIPE therapy, daily nursing assessment should include:

• Liver function: Symptoms of hepatotoxicity (nausea, vomiting, right upper quadrant pain, jaundice, dark urine) — primarily isoniazid and rifampin; baseline and periodic LFTs
• Visual changes: Assess visual acuity and color vision (red-green color discrimination) monthly in patients on ethambutol
• Peripheral symptoms: Tingling, numbness, or burning in hands and feet (INH-induced peripheral neuropathy)
• Urine color: Rifampin turns urine, tears, saliva, and contact lenses orange-red — educate patients this is expected and harmless

RIPE therapy and drug monitoring

The standard 6-month regimen

Standard treatment for drug-susceptible active pulmonary TB follows a two-phase protocol per CDC/ATS/IDSA guidelines (2016 update):

Phase 1 — Initial phase (2 months): Rifampin (R) + Isoniazid (I) + Pyrazinamide (Z/P) + Ethambutol (E) — the full RIPE regimen. All four drugs are used simultaneously to achieve rapid bacterial kill and prevent emergence of resistance.

Phase 2 — Continuation phase (4 months): Rifampin (R) + Isoniazid (I) only. Pyrazinamide and ethambutol are stopped once susceptibility results confirm full drug susceptibility and the patient achieves sputum culture conversion (three consecutive negative cultures).

Total treatment duration: 6 months minimum for drug-susceptible pulmonary TB without cavitation and with negative sputum cultures at 2 months. Treatment extends to 9 months if sputum cultures remain positive at 2 months or if cavitary disease was present at baseline.

Pyridoxine (vitamin B6) supplementation

Isoniazid competitively inhibits pyridoxal phosphate (the active form of vitamin B6), which is required for peripheral nerve myelin synthesis. Without pyridoxine supplementation, INH causes peripheral neuropathy — paresthesias, burning, and numbness in a stocking-glove distribution — in a dose-dependent manner. CDC/ATS guidelines recommend pyridoxine 25–50 mg/day for all patients on INH who are at increased risk for neuropathy:

• Pregnancy and breastfeeding
• Diabetes mellitus
• HIV infection
• Alcohol use disorder
• Malnutrition
• Renal failure
• Age ≥65 years

In clinical practice, pyridoxine is co-prescribed routinely with INH for most adult patients. This is a high-yield NCLEX nursing consideration: when a patient on isoniazid reports tingling in the hands and feet, the first nursing action is to assess pyridoxine administration and notify the provider.

Sputum culture conversion

The key indicator of treatment response is sputum culture conversion — the change from positive to negative mycobacterial cultures. Patients should be monitored with monthly sputum AFB smears and cultures until two consecutive negative cultures are documented. The time to culture conversion is important: patients whose cultures remain positive at the 2-month mark have a higher risk of treatment failure and require extended therapy. Sputum conversion typically occurs by 2 months in approximately 80% of patients on standard RIPE therapy.

Drug-resistant TB

MDR-TB (multidrug-resistant TB) is defined as resistance to at least rifampin and isoniazid — the two most effective first-line TB drugs. MDR-TB requires 18–24 months of treatment with second-line agents (fluoroquinolones, injectable aminoglycosides, bedaquiline, linezolid, clofazimine). The nursing burden of MDR-TB is substantially higher: longer treatment duration, more toxic drugs, and more complex DOT logistics.

XDR-TB (extensively drug-resistant TB) is resistance to INH, rifampin, any fluoroquinolone, and at least one injectable second-line drug. XDR-TB is associated with very high mortality and represents a public health emergency requiring immediate notification.

Risk factors for drug-resistant TB include: prior TB treatment (especially incomplete courses), contact with a known drug-resistant case, HIV infection, birth in a country with high MDR-TB prevalence (Russia, former Soviet republics, India, China, South Africa), and non-adherent treatment under self-administration (rather than DOT). This is why DOT is not bureaucratic procedure — it is the primary prevention strategy for MDR-TB.

Patient education

Patient education is a core nursing responsibility in TB care and directly impacts treatment completion, infection control, and prevention of drug resistance.

Treatment adherence

Explain to the patient and family:

• TB requires a full 6 months of treatment — stopping early when symptoms improve will not cure TB and risks developing drug-resistant disease
• Missing doses is the primary cause of treatment failure and drug resistance
• DOT is in place to support them, not to punish them — the nurse or community health worker is a resource, not a monitor
• Public health TB programs can provide transportation, food incentives, and other support for DOT attendance

Infection control at home

• Stay home from work, school, and public spaces during the infectious period (first 2 weeks of effective therapy at minimum; follow public health guidance)
• Avoid enclosed, poorly ventilated spaces — ventilation is the key environmental control measure
• Cover mouth and nose when coughing or sneezing; use tissues and dispose immediately
• Household members should be evaluated for TB infection by the local health department — contact tracing is a public health responsibility, but the nurse should reinforce its importance

Medication-specific education

• Rifampin: Urine, sweat, and tears will turn orange-red — this is harmless and expected
• Contact lenses: Rifampin permanently stains soft contact lenses — wear glasses during treatment
• Oral contraceptives: Rifampin reduces OC efficacy — use barrier contraception
• Isoniazid: Take pyridoxine (vitamin B6) as prescribed; report any tingling or numbness immediately
• All four drugs: Report nausea, abdominal pain, yellowing of skin or eyes, or dark urine immediately — these may signal hepatotoxicity requiring drug discontinuation

Follow-up sputum cultures

Patients must understand that symptom improvement does not confirm bacteriological cure. Monthly sputum cultures are required to confirm culture conversion and track treatment response. Missed follow-up cultures prevent the provider from detecting treatment failure early.

When to seek care immediately

Instruct patients to go to the ED or call the provider for:

• Jaundice, dark urine, or clay-colored stools (hepatotoxicity)
• Any change in vision (optic neuritis from ethambutol)
• Worsening shortness of breath or chest pain (disease progression, pneumothorax)
• Hemoptysis (coughing up blood)
• Fever above 39°C despite being on treatment

NCLEX-style questions

Question 1

A nurse is admitting a patient with suspected active pulmonary tuberculosis. Which is the nurse’s priority action?

A. Obtain three sputum specimens for AFB smear and culture B. Administer the first dose of isoniazid as ordered C. Place the patient in a negative pressure room and don an N95 respirator D. Notify the local public health department of the suspected case

Correct answer: C

Rationale: Infection control is the immediate nursing priority to prevent transmission to other patients and healthcare workers. The patient must be placed in an airborne infection isolation room (negative pressure) and the nurse must wear an N95 respirator — not a surgical mask — before any assessment or care. Obtaining sputum specimens (A) and administering medications (B) are important but follow after isolation is established. Reporting to public health (D) is required but is not the first action.

Question 2

A nurse is educating a patient who will begin RIPE therapy for active TB. Which statement by the patient indicates a need for further teaching?

A. “I should take my vitamin B6 pill every day with my isoniazid.” B. “My urine turning orange is a sign that I need to stop the rifampin.” C. “I will need to use a different form of birth control while on this treatment.” D. “I need to have my vision checked every month while I’m taking the ethambutol.”

Correct answer: B

Rationale: Orange discoloration of urine, tears, saliva, and sweat is an expected, harmless side effect of rifampin caused by an excreted metabolite. Patients should be told to expect this before starting treatment so they are not alarmed. It is not a reason to stop rifampin. Statement A is correct — pyridoxine (B6) prevents INH-induced peripheral neuropathy. Statement C is correct — rifampin is a potent CYP450 inducer that reduces oral contraceptive efficacy. Statement D is correct — monthly visual acuity and color vision testing is required for patients on ethambutol to detect optic neuritis early.

Question 3

A nurse is caring for a patient with active TB who has been on RIPE therapy for 8 days. The patient’s sputum AFB smear is still positive. The patient asks to go to the hospital cafeteria for lunch with family. Which response is correct?

A. Allow the patient to go — after 7 days of treatment, TB is no longer contagious B. Allow the patient to go if they wear a surgical mask C. Explain that the patient must remain in airborne isolation until three consecutive negative AFB smears are obtained, clinical improvement is documented, and at least 2 weeks of effective therapy have been completed D. Explain that the patient can leave the room as long as all family members wear N95 respirators

Correct answer: C

Rationale: Criteria for discontinuing airborne precautions require all three conditions: (1) three consecutive negative sputum AFB smears collected ≥8 hours apart, (2) clinical improvement, AND (3) a minimum of 2 weeks of effective therapy. All three conditions must be met simultaneously. A positive smear at 8 days means the patient is still potentially infectious regardless of symptom improvement. Surgical masks (B) do not filter airborne droplet nuclei — they are appropriate for the patient to wear during transport but do not permit removal from isolation. Option D is incorrect because the patient wearing no mask in a public space poses risk to all persons present, not just family.

Question 4

A patient on isoniazid reports numbness and tingling in both feet. Which nursing action is most appropriate?

A. Reassure the patient that this is an expected side effect of isoniazid and requires no intervention B. Assess whether the patient has been taking pyridoxine (vitamin B6) as prescribed and notify the provider C. Stop the isoniazid immediately and notify the provider D. Obtain liver function tests immediately, as this finding indicates hepatotoxicity

Correct answer: B

Rationale: Peripheral neuropathy (paresthesias — numbness, tingling, burning) is a recognized side effect of isoniazid due to pyridoxal phosphate depletion. The first nursing actions are to assess pyridoxine adherence (B6 supplementation prevents neuropathy in most patients) and notify the provider. Peripheral neuropathy is not an expected, untreated side effect (A is incorrect). The nurse should not stop isoniazid without a provider order (C) — the provider may adjust pyridoxine dosing and continue INH if the neuropathy is mild. Peripheral neuropathy is not a sign of hepatotoxicity (D) — hepatotoxicity presents with nausea, vomiting, RUQ pain, and jaundice.

Question 5

Which patient is at highest risk for reactivation of latent TB infection?

A. A 35-year-old with positive TST who immigrated from India 15 years ago and has no chronic illnesses B. A 52-year-old with type 2 diabetes starting adalimumab (Humira) therapy for rheumatoid arthritis C. A 28-year-old healthcare worker with a new TST conversion who works in a respiratory unit D. A 60-year-old with COPD receiving inhaled corticosteroids for 10 years

Correct answer: B

Rationale: Anti-TNF agents such as adalimumab dramatically increase the risk of TB reactivation because TNF-alpha is essential for granuloma formation and maintenance — the immune mechanism that contains latent TB. Patients with LTBI who start anti-TNF therapy have approximately a 5–25 times higher risk of reactivation compared to TNF-naive patients. Screening for LTBI with TST or IGRA before starting any anti-TNF agent is mandatory, and LTBI must be treated before biologic initiation. Diabetes (also in this patient) independently increases TB risk 2–3 fold, making this patient’s risk even higher. Options A and C describe LTBI without active immunosuppression. Option D (inhaled corticosteroids) poses low systemic immunosuppressive risk compared to biologic TNF blockade.

Question 6

A public health nurse explains directly observed therapy (DOT) to a newly diagnosed active TB patient who wants to self-administer medications at home. Which statement best explains the rationale for DOT?

A. “DOT is a legal requirement — patients with TB are mandated by law to use it.” B. “DOT is used to monitor you for drug side effects at each visit.” C. “DOT ensures every dose is taken as prescribed, which prevents treatment failure and the development of drug-resistant TB strains.” D. “DOT is required because TB medications are controlled substances that cannot be dispensed for home use.”

Correct answer: C

Rationale: The evidence-based rationale for DOT is prevention of treatment failure and drug resistance. Non-adherence — even missing occasional doses — allows partially susceptible organisms to survive and replicate, creating selective pressure for resistant mutants. MDR-TB (resistant to rifampin and isoniazid, the two most effective drugs) is predominantly driven by prior inadequate treatment. DOT eliminates missed doses and is the CDC/WHO-recommended standard of care. Option A overstates the legal dimension — while health departments do have legal authority for non-adherent infectious patients, DOT itself is not universally legally mandated; it is a clinical and public health standard. Option B (side effect monitoring) is a secondary benefit, not the primary rationale. Option D is factually incorrect — TB medications are not controlled substances.

Related references

• Pneumonia nursing reference — TB can mimic or co-exist with bacterial pneumonia; compare assessment findings and antibiotic management
• Sepsis nursing reference — disseminated TB and miliary TB can cause sepsis syndrome; review Sepsis-3 criteria and the 1-hour bundle
• MRSA nursing reference — compare airborne (TB) vs contact (MRSA) precautions; infection control principles for infectious disease nursing
• C. diff nursing reference — contact precautions and isolation principles; infection control cluster reference
• Drug classifications nursing reference — pharmacology context for the RIPE regimen and antibiotic classes
• Nursing lab values cheat sheet — LFT interpretation for hepatotoxicity monitoring; CBC for treatment response; uric acid for pyrazinamide monitoring
• Wound assessment guide — assessment of draining wounds and sinuses in extrapulmonary (osteoarticular) TB
• HIV/AIDS nursing reference — HIV is the single greatest risk factor for TB reactivation; TB/HIV co-infection management, CD4 thresholds, and ART drug interactions with the RIPE regimen